[Platelets activation in depending on glycaemic control in diabetes type 2].

Pol Merkur Lekarski

Uniwersytet Medyczny w Białymstoku, Zakład Laboratoryjnej Diagnostyki Klinicznej.

Published: October 2008


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Unlabelled: Both metabolic and heamodynamic disorders accompany diabetes. Inadequate control of glycaemia, glication proteins and oxidative stress causes chronic thromboembolic and atherothrombosis complications. Disorders which are observed in diabetes induce intravascular platelets activation and changes with platelets' morphologic parameters. It is interesting if this process depends on glycaemic control diabetes? The aim of our study was to investigate in patients with type 2 diabetes the level of beta-thromboglobulin as the platelets activation marker and platelet count (PLT), mean platelet volume (MPV), which depend on diabetes control.

Material And Methods: The study group included 58 patients with type 2 diabetes (middle ages was 58) with long-term anamnesis and treated only with insulin. The control group was composed by 36 healthy people (middle ages was 54). The study group was categorized into two subgroups, in depending on percent of glycosylated haemoglobin (HbA1c) which is a marker of diabetes control: B1--HbA1c < 7,5%--(13 people), B2--HbA1c > or = 7,5%--(45 people). Identical set research (beta-TG, PLT MPV and HbA1c) were carried out in both study group and the control group. Blood samples were collected from elbow vein, with no staza use and were put to test- tubes with disodium versenate (EDTA-K2) and to vacuum test- tubes Vacutainer with anticoagulant CTAD.

Results: We didn't observe significantly important differences in the research parameters: B-TG, MPV and PLT between subgroups with good diabetes control and worse diabetes control. The level of beta-thromboglobulin and the mean platelet volume was significantly important higher in the study group than in the control subjects. However, PLT--platelet count, in the blood collected from patients with type 2 diabetes was slightly lower than in the control group.

Conclusion: Increased activation of platelets in patients with type 2 diabetes does not depend on glycaemic control diabetes.

Download full-text PDF

Source

Publication Analysis

Top Keywords

patients type
16
type diabetes
16
study group
16
glycaemic control
12
diabetes
12
diabetes control
12
control
11
control diabetes
8
platelets activation
8
level beta-thromboglobulin
8

Similar Publications

Importance: As obesity rates rise in the US, managing associated metabolic comorbidities presents a growing burden to the health care system. While bariatric surgery has shown promise in mitigating established metabolic conditions, no large studies have quantified the risk of developing major obesity-related comorbidities after bariatric surgery.

Objective: To identify common metabolic phenotypes for patients eligible for bariatric surgery and to estimate crude and adjusted incidence rates of additional metabolic comorbidities associated with bariatric surgery compared with weight management program (WMP) alone.

View Article and Find Full Text PDF

Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.

Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.

Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.

View Article and Find Full Text PDF

Indigenous Peoples experience the highest age-adjusted prevalence of type 2 diabetes of any racial group in the U.S. Though the management of type 2 diabetes requires regular healthcare visits, North American Indigenous individuals with diabetes do not always utilize the healthcare available to them, and this lack of utilization may lead to poor health outcomes over time.

View Article and Find Full Text PDF

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have gained prominence for their efficacy in treating type 2 diabetes and obesity. Recent evidence suggests that their pleiotropic effects-beyond glycemic control and weight loss-include anti-inflammatory, immunomodulatory, and antioxidative effects, which may beneficially support various dermatologic conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease. However, GLP-1 RAs are also associated with emerging cutaneous adverse drug reactions, including bullous, exanthematous and vasculitic manifestations, and other rare side effects.

View Article and Find Full Text PDF

Purpose: This study aimed to evaluate the prognostic significance of microvessel density (MVD), assessed by CD34 immunohistochemistry (IHC), and its correlation with radiological features and bevacizumab (BEV) treatment efficacy in newly diagnosed glioblastoma.

Methods: We retrospectively analyzed 41 patients with newly diagnosed glioblastoma. MVD was quantified using CD34 IHC, and patients were stratified into low and high MVD groups according to the cutoff value determined by receiver operating characteristic curve analysis (sensitivity, 76.

View Article and Find Full Text PDF